On September 12, 2025, Qingdao Baheal Medical INC. (Stock Code: 301015.SZ) entered into a strategic collaboration with Tianjin JiKun Medicine Technology Co., Ltd. As part of this agreement, Baheal will acquire a 24% stake in JiKun Medicine, securing full rights to its Class I innovative drug for pulmonary fibrosis. In addition, Baheal gains the right of first refusal—under equivalent terms—on the global compound rights of all JiKun pipeline assets.

Recently, BrioHealth Solutions, Inc., a wholly-owned subsidiary of BrioHealth in the United States, announced that its independently developed fully magnetic levitation left ventricular assist device, BrioVAD, has formally received approval from FDA to advance to the Pivotal Phase of its clinical trial following the successful completion of the Safety Phase of the INNOVATE clinical trial in the United States. The FDA has approved expanding the clinical research centers to 60 sites, with a cumulative enrollment of up to 780 subjects (including those enrolled during the Safety Phase).

On May 16, 2025, Qingdao Baheal Pharma Co., Ltd, a subsidiary of Baheal Pharma under Baheal Medical (301015.SZ), held a relocation ceremony to celebrate its Phase III construction project. Mr. Zhu Xiaowei, Director of Baheal Pharma Group, Vice President of Baheal Medical and Chairman of Baheal Pharma, Mr. Hao Yu, Vice President of Baheal Pharma Group's Campus Operation, Ms. Zheng Aiju, General Manager of Qingdao Baheal Pharma, and other leaders and guests, as well as colleagues of Qingdao Baheal Pharma, were present at the ceremony to witness this important moment together.

On April 18, 2025, the highly anticipated “China Venture Annual Awards 2024” was officially released. Thanks to the firm’s strategic foresight in backing medical original innovations and its growing influence in early-stage life science investments, Baheal Pharma Group’s investment vehicle—BAHEAL ZHONGXIN CAPITAL—secured a place in the “2024 China Top 50 Corporate Direct‐Investment Funds”, underscoring its professional strength and industry influence in the early-stage life-health investment area.

On March 20, 2025, State Key Laboratory of Cardiovascular Disease officially opened in Shenzhen, accompanied by the inaugural meeting of its Academic Committee. The ceremony gathered senior government officials, leading scientists, and industry partners, including Huang Xiangyue, Party Secretary of Nanshan District; Wu Hongyan, Director of Shenzhen Municipal Health Commission; Chen Yihan, Academician of the Chinese Academy of Sciences and President of Shanghai East Hospital, Tongji University; Hu Shengshou, Academician of the Chinese Academy of Engineering, President of Fuwai Hospital, and Director of State Key Laboratory of Cardiovascular Disease; as well as Fu Gang, Chairman of Baheal Pharma Group.